Znaczenie wczesnego wdrożenia terapii wysoko efektywnych w świetle najnowszych danych klinicznych o okrelizumabie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2026
Słowa kluczowe:
stwardnienie rozsiane, łagodne stwardnienie rozsiane, okrelizumab, terapia wysoko efektywna, PIRA
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wczesne wdrożenie terapii wysoko efektywnych stanowi obecnie kluczową strategię w leczeniu stwardnienia rozsianego, ukierunkowaną na ograniczenie ryzyka postępu choroby. Okrelizumab – humanizowane przeciwciało monoklonalne anty-CD20 – ma udowodnioną dużą skuteczność zarówno w rzutowo-remisyjnej, jak i w pierwotnie postępującej postaci stwardnienia rozsianego. W pracy opisano korzyści wynikające z wczesnego rozpoczęcia leczenia okrelizumabem.
Wyniki badań klinicznych oraz dane z rzeczywistej praktyki klinicznej wskazują, że pacjenci leczeni we wczesnej fazie choroby osiągają niższy roczny wskaźnik rzutów, stabilizację radiologiczną oraz wolniejszą progresję potwierdzonej niepełnosprawności niż pacjenci, u których zastosowano strategię eskalacyjną. Wczesne zastosowanie okrelizumabu wiąże się również z korzystnym wpływem na zmniejszenie tempa zaniku objętości mózgu, co sugeruje potencjalną rolę leku w ograniczaniu uszkodzenia neuroaksonalnego już na wczesnych etapach choroby. Długoterminowe dane obserwacyjne potwierdzają trwałość efektów terapeutycznych przy akceptowalnym profilu bezpieczeństwa.
Podsumowując – dostępne dowody podkreślają istotne znaczenie wczesnego wdrożenia terapii wysoko efektywnych, takich jak zastosowanie okrelizumabu. Rozpoczęcie leczenia na wczesnym etapie stwardnienia rozsianego może przyczynić się do ograniczenia ryzyka odległych następstw choroby. Wyniki te potwierdzają sugestie o zmianie paradygmatu leczenia w kierunku wczesnego zastosowania terapii o wysokiej skuteczności u odpowiednio dobranych pacjentów.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright ? by Medical Education. All rights reserved.
Bibliografia
1. Walton C, King R, Rechtman L et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26(14): 1816-21.
2. Hartung HP, Meuth SG, Aktas O et al. Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. Mult Scler. 2021; 27(13): 1985-97.
3. Filippi M, Amato MP, Centonze D et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022; 269(10): 5382-94.
4. Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022; 82(3): 323-34.
5. Kułakowska A, Mirowska-Guzel D, Kalinowska A et al. Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society. Neurol Neurochir Pol. 2024; 58(6): 569-85.
6. Freedman MS, Devonshire V, Duquette P et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020; 47(4): 437-55.
7. Kappos L, De Stefano N, Freedman MS et al. Inclusion of brain volume loss in a revised measure of ‚no evidence of disease activity’ (NEDA-4) in relapsing- remitting multiple sclerosis. Mult Scler. 2016; 22(10): 1297-305.
8. Bose G, Healy BC, Saxena S et al. Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. Mult Scler. 2020; 26(12): 1555-64.
9. Wijmeersch BV, Vermersch P, Hartung HP et al. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide. Front Immunol. 2022; 13: 991291.
10. Morgan J, Huynh W, Barnett MH et al. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Rev Neurother. 2023; 23(6): 549-62.
11. Fernandez O. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017; 17: 75-83.
12. Iaffaldano P, Lucisano G, Caputo F et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021; 14: 17562864211019574.
13. Simonsen CS, Flemmen HØ, Broch L et al. Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. Front Neurol. 2021; 12: 693017.
14. Hawkins SA, Mcdonnell GV. Benign multiple sclerosis? Clinical course, long term follow up and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999; 67(2): 148-52.
15. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46(4): 907-11.
16. Ramsaransing GSM, De Keyser J. Benign course in multiple sclerosis: a review. Acta Neurol Scand. 2006; 113: 359-69.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11): 1444-52.
18. Tallantyre EC, Causon EG, Harding KE et al. How common is truly benign MS in a UK population? J Neurol Neurosurg Psychiatry. 2019; 90(5): 522-28.
19. Ellenberger D, Flachenecker P, Haas J et al. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. Mult Scler Relat Disord. 2020; 46: 102485.
20. Matas E, Bau L, Romero-Pinel L et al. Benign multiple sclerosis and long-term outcomes after 30 years. J Neurol. 2025; 272(11): 747.
21. Amato MP, Prestipino E, Bellinvia A. Truly benign multiple sclerosis is rare: let’s stop fooling ourselves – Yes. Mult Scler. 2012; 18(1): 15-7.
22. Sharmin S, Leocani L, Hillert J et al. Standardized definition of progression independent of relapse activity (PIRA) in relapsingremitting multiple sclerosis. JAMA Neurol. 2025; 82(2): 1-9.
23. Cagol A, Schaedelin S, Barakovic M et al. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 2022; 79(7): 682-92.
24. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015; 14(2): 183-93.
25. Portaccio E, Bellinvia A, Fonderico M et al. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression. J Neurol. 2024; 271(7): 4528-38.
26. Massacesi L, Tramacere I, Amoroso S et al. Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis. J Clin Med. 2022; 11(15): 4288.
27. Kappos L, Radue EW, Comi G et al. Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2023; 270(11): 5509-21.
28. Kappos L, Wolinsky JS, Giovannoni G et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020; 77(9): 1132-40.
29. Ingwersen J, Aktas O, Kuempfel T et al. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials. Sci Rep. 2023; 13(1): 14940.
30. Cerqueira JJ, Compston DAS, Geraldes R et al. Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension. Neurology. 2025; 104(3): e210142.
31. Bermel R, Hartung HP, Brochet B et al. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing- Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004). MS Therapeutics and Clinical Decision Making. 2023; 100(17, suppl. 2): 1928.
32. Hartung HP, Aktas O, Boyko AN et al. Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial. Neurology. 2024; 103(8): e210049.
33. Buttmann M, Brück W, Hecker M et al. CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany. Front Neurol. 2025; 16: 1564327.
34. Lanzillo R, Sparaco M, Lavorgna L et al. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. J Clin Med. 2022; 11(8): 2081.
35. Cellerino M, Cordano C, Boffa G et al. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics. 2021; 18(4): 2579-88.
36. Guerra T, Coppola L, Maida E et al. Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort. Drug Saf. 2025; 48(2): 1-13.
37. Hauser SL, Kappos L, Montalban X et al. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 2021; 97(16): e1546-59.
2. Hartung HP, Meuth SG, Aktas O et al. Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. Mult Scler. 2021; 27(13): 1985-97.
3. Filippi M, Amato MP, Centonze D et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022; 269(10): 5382-94.
4. Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022; 82(3): 323-34.
5. Kułakowska A, Mirowska-Guzel D, Kalinowska A et al. Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society. Neurol Neurochir Pol. 2024; 58(6): 569-85.
6. Freedman MS, Devonshire V, Duquette P et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020; 47(4): 437-55.
7. Kappos L, De Stefano N, Freedman MS et al. Inclusion of brain volume loss in a revised measure of ‚no evidence of disease activity’ (NEDA-4) in relapsing- remitting multiple sclerosis. Mult Scler. 2016; 22(10): 1297-305.
8. Bose G, Healy BC, Saxena S et al. Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. Mult Scler. 2020; 26(12): 1555-64.
9. Wijmeersch BV, Vermersch P, Hartung HP et al. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide. Front Immunol. 2022; 13: 991291.
10. Morgan J, Huynh W, Barnett MH et al. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Rev Neurother. 2023; 23(6): 549-62.
11. Fernandez O. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017; 17: 75-83.
12. Iaffaldano P, Lucisano G, Caputo F et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021; 14: 17562864211019574.
13. Simonsen CS, Flemmen HØ, Broch L et al. Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. Front Neurol. 2021; 12: 693017.
14. Hawkins SA, Mcdonnell GV. Benign multiple sclerosis? Clinical course, long term follow up and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999; 67(2): 148-52.
15. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46(4): 907-11.
16. Ramsaransing GSM, De Keyser J. Benign course in multiple sclerosis: a review. Acta Neurol Scand. 2006; 113: 359-69.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11): 1444-52.
18. Tallantyre EC, Causon EG, Harding KE et al. How common is truly benign MS in a UK population? J Neurol Neurosurg Psychiatry. 2019; 90(5): 522-28.
19. Ellenberger D, Flachenecker P, Haas J et al. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. Mult Scler Relat Disord. 2020; 46: 102485.
20. Matas E, Bau L, Romero-Pinel L et al. Benign multiple sclerosis and long-term outcomes after 30 years. J Neurol. 2025; 272(11): 747.
21. Amato MP, Prestipino E, Bellinvia A. Truly benign multiple sclerosis is rare: let’s stop fooling ourselves – Yes. Mult Scler. 2012; 18(1): 15-7.
22. Sharmin S, Leocani L, Hillert J et al. Standardized definition of progression independent of relapse activity (PIRA) in relapsingremitting multiple sclerosis. JAMA Neurol. 2025; 82(2): 1-9.
23. Cagol A, Schaedelin S, Barakovic M et al. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 2022; 79(7): 682-92.
24. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015; 14(2): 183-93.
25. Portaccio E, Bellinvia A, Fonderico M et al. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression. J Neurol. 2024; 271(7): 4528-38.
26. Massacesi L, Tramacere I, Amoroso S et al. Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis. J Clin Med. 2022; 11(15): 4288.
27. Kappos L, Radue EW, Comi G et al. Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2023; 270(11): 5509-21.
28. Kappos L, Wolinsky JS, Giovannoni G et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020; 77(9): 1132-40.
29. Ingwersen J, Aktas O, Kuempfel T et al. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials. Sci Rep. 2023; 13(1): 14940.
30. Cerqueira JJ, Compston DAS, Geraldes R et al. Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension. Neurology. 2025; 104(3): e210142.
31. Bermel R, Hartung HP, Brochet B et al. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing- Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004). MS Therapeutics and Clinical Decision Making. 2023; 100(17, suppl. 2): 1928.
32. Hartung HP, Aktas O, Boyko AN et al. Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial. Neurology. 2024; 103(8): e210049.
33. Buttmann M, Brück W, Hecker M et al. CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany. Front Neurol. 2025; 16: 1564327.
34. Lanzillo R, Sparaco M, Lavorgna L et al. Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. J Clin Med. 2022; 11(8): 2081.
35. Cellerino M, Cordano C, Boffa G et al. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics. 2021; 18(4): 2579-88.
36. Guerra T, Coppola L, Maida E et al. Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort. Drug Saf. 2025; 48(2): 1-13.
37. Hauser SL, Kappos L, Montalban X et al. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 2021; 97(16): e1546-59.